The termination poses no disruption to Beam's IP access due to the pre-arranged standby license. Monitor Beam's R&D progress in base editing, as the seamless transition supports ongoing development programs without legal or operational risk from the Bio Palette dissolution.
Price Chart
Executive Summary
Beam Therapeutics Inc. (BEAM) and Bio Palette Co., Ltd. mutually terminated their 2019 License Agreement due to Bio Palette's planned dissolution. A standby license from Kobe University has been activated, ensuring Beam retains the same patent rights previously licensed through Bio Palette. No termination fees are owed, and all future payments between Beam and Bio Palette have ceased.
Key Facts
- Beam Therapeutics and Bio Palette mutually terminated their 2019 License Agreement on March 2, 2026.
- The termination was due to the planned dissolution of Bio Palette.
- A standby license from Kobe University has been activated, granting Beam the same exclusive patent rights as before.
- No future payments are due between Beam and Bio Palette, and there are no termination fees.
- The agreement involved cross-licensing of base editing patents for human therapeutics and microbiome products in Asia.
Financial Impact
No direct financial impact — no termination fees or future payments. Strategic continuity maintained via standby license.
Risk Factors
- Potential future complications if Kobe University challenges the scope or enforceability of the standby license.
- Loss of collaborative development or commercialization opportunities previously enabled by Bio Palette in the Asian microbiome market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-093914 |
| Document: 0001193125-26-093914-index-headers.html | 0001193125-26-093914 |
| Document: 0001193125-26-093914-index.html | 0001193125-26-093914 |
| Document: 0001193125-26-093914.txt | 0001193125-26-093914 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $27.10 $23.22 | ▼ −14.32% | ▼ −12.34% | $24.50 (−9.59%) |
Jul 2, 2026 13w ago | Insider Cluster | $34.79 $26.49 | ▼ −23.86% | ▼ −23.44% | $24.50 (−29.58%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.48 $26.02 | ▲ +22.28% | ▲ +20.10% | $24.50 (+26.82%) |
May 12, 2026 20w ago | Press Release | $31.58 $29.49 | ▼ −6.62% | ▼ −4.89% | $24.50 (−22.42%) |
Apr 17, 2026 24w ago | DEFA14A | $31.19 $26.81 | ▼ −14.04% | ▼ −18.25% | $24.50 (−21.45%) |
Mar 25, 2026 27w ago | Press Release | $23.12 $30.16 | ▲ +30.45% | ▲ +22.59% | $24.50 (+5.97%) |
Mar 5, 2026 30w ago | 8-K | $26.54 $24.23 | ▼ −8.70% | ▼ −6.66% | $24.50 (−7.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access